

CONTENTS

EDITORIAL

- 1947** Regarding: 'Epoetin β treatment in patients with cancer chemotherapy induced anaemia: the impact of initial haemoglobin and target haemoglobin levels on survival, tumour progression and thromboembolic events'
G Schwarzer

REVIEW

- 1949** Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth
AM Traish and A Morgentaler

CLINICAL STUDIES

- 1957** Vitamin D receptor polymorphisms and prognosis of patients with epithelial ovarian cancer
S Tamez, C Norizoe, K Ochiai, D Takahashi, A Shimojima, Y Tsutsumi, N Yanaihara, T Tanaka, A Okamoto and M Urashima
- 1961** Epoetin- β treatment in patients with cancer chemotherapy-induced anaemia: the impact of initial haemoglobin and target haemoglobin levels on survival, tumour progression and thromboembolic events
M Aapro, B Osterwalder, A Scherhag and HU Burger
- 1972** Phase I/II study of sequential therapy with irinotecan and S-1 for metastatic colorectal cancer
T Yoshioka, S Kato, M Gamoh, N Chiba, T Suzuki, N Sakayori, S Kato, H Shibata, H Shimodaira, K Otsuka, Y Kakudo, S Takahashi and C Ishioka
- 1978** Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial
P Bougnoux, N Hajjaji, MN Ferrasson, B Giraudeau, C Couet and O Le Floch

- 1986** Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study
DA Reardon, A Desjardins, JJ Vredenburgh, S Gururangan, JH Sampson, S Sathornsumetee, RE McLendon, JE Hemdon II, JE Marcello, J Norfleet, AH Friedman, DD Bigner and HS Friedman

- 1995** Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma
DA Reardon, G Dresemann, S Taillibert, M Campone, M van den Bent, P Clement, E Blomquist, L Gordower, H Schultz, J Raizer, P Hau, J Easaw, M Gil, J Tonn, A Gijtenbeek, U Schlegel, P Bergstrom, S Green, A Weir and Z Nikolova

TRANSLATIONAL THERAPEUTICS

- 2005** Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma
V Bilim, A Ougolkov, K Yuuki, S Naito, H Kawazoe, A Muto, M Oya, D Billadeau, T Motoyama and Y Tomita
- 2015** *In vivo* high-resolution fluorescence microendoscopy for ovarian cancer detection and treatment monitoring
W Zhong, JP Celli, I Rizvi, Z Mai, BQ Spring, SH Yun and T Hasan

MOLECULAR DIAGNOSTICS

- 2023** Self-production of tissue factor-coagulation factor VII complex by ovarian cancer cells
N Yokota, S Koizume, E Miyagi, F Hirahara, Y Nakamura, K Kikuchi, W Ruf, Y Sakuma, E Tsuchiya and Y Miyagi
- 2030** Tumour formation by single fibroblast growth factor receptor 3-positive rhabdomyosarcoma-initiating cells
M Hirotsu, T Setoguchi, Y Matsunoshita, H Sasaki, H Nagao, H Gao, K Sugimura and S Komiya
- 2038** Epac inhibits migration and proliferation of human prostate carcinoma cells
M Grandoch, A Rose, M ter Braak, V Jendrosseck, H Rübben, JW Fischer, M Schmidt and AA Weber



GENETICS AND GENOMICS

- 2043** **Absence of truncating BRIP1 mutations in chromosome 17q-linked hereditary prostate cancer families**
AM Ray, KA Zuhlke, GR Johnson, AM Levin, JA Douglas, EM Lange and KA Cooney
- 2048** **Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA)**
A Osorio, RL Milne, G Pita, P Peterlongo, T Heikkinen, J Simard, G Chenevix-Trench, AB Spurdle, J Beesley, X Chen, S Healey, KConFab, SL Neuhausen, YC Ding, FJ Couch, X Wang, N Lindor, S Manoukian, M Barile, A Viel, L Tizzoni, CI Szabo, L Foretova, M Zikan, K Claes, MH Greene, P Mai, G Rennert, F Lejbkowitz, O Barnett-Griness, IL Andrulis, H Ozcelik, N Weerasooriya, OCGN A-M Gerdes, M Thomassen, DG Cruger, MA Caligo, E Friedman, B Kaufman, Y Laitman, S Cohen, T Kontorovich, R Gershoni-Baruch, E Dagan, H Jemström, MS Askmalm, B Arver, B Malmer, SWE-BRCA, SM Domchek, KL Nathanson, J Brunet, T Ramón y Cajal, D Yannoukakis, U Hamann, HEBON, FBL Hogervorst, S Verhoef, EB Gómez García, JT Wijnen, A van den Ouweland, EMBRACE, DF Easton, S Peock, M Cook, CT Oliver, D Frost, C Luccarini, DG Evans, F Lalloo, R Eeles, G Pichert, J Cook, S Hodgson, PJ Morrison, F Douglas, AK Godwin, GEMO, OM Sinilnikova, L Barjhoux, D Stoppa-Lyonnet, V Moncoutier, S Giraud, C Cassini, L Olivier-Faivre, F Révillion, J-P Peyrat, D Muller, J-P Fricker, HT Lynch, EM John, S Buys, M Daly, JL Hopper, MB Terry, A Miron, Y Yassin, D Goldgar, Breast Cancer Family Registry, CF Singer, D Gschwantler-Kaulich, G Pfeiler, A-C Spiess, Thomas v. O. Hansen, OT Johannsson, T Kirchoff, K Offit, K Kosarin, M Piedmonte, GC Rodriguez, K Wakeley, JF Boggess, J Basil, PE Schwartz, SV Blank, AE Toland, M Montagna, C Casella, EN Imyanitov, A Allavena, RK Schmutzler, B Versmold, C Engel, A Meindl, N Ditsch, N Arnold, D Niederacher, H Deißler, B Fiebig, R Varon-Mateeva, D Schaefer, UG Froster, T Caldes, M de la Hoya, L McGuffog, AC Antoniou, H Nevanlinna, P Radice and J Benítez on behalf of CIMBA

LETTERS TO THE EDITOR

- 2055** **Regarding: 'High-intensity-focused ultrasound in the treatment of primary prostate cancer: the first UK series'**
TS Clark
- 2056** **Reply to TS Clark: 'High-intensity-focused ultrasound in the treatment of primary prostate cancer: the first UK series'**
HU Ahmed and M Emberton

- 2057** **Regarding: 'High-intensity-focused ultrasound in the treatment of primary prostate cancer: the first UK series'**
S Eggener, M Gonzalgo and O Yossepowitch
- 2059** **Reply to S Eggener, M Gonzalgo and O Yossepowitch: 'High-intensity-focused ultrasound in the treatment of primary prostate cancer: the first UK series'**
HU Ahmed and M Emberton
- 2060** **Evolutionary game theory: lessons and limitations, a cancer perspective**
JW McEvoy
- 2062** **Reply: Evolutionary game theory: lessons and limitations, a cancer perspective**
D Dingli, FACC Chalub, FC Santos, S Van Segbroeck and JM Pacheco

CORRIGENDUM

- 2064** **Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways**
A-M Cleton-Jansen, JK Anninga, IH Briaire-de Bruijn, S Romeo, J Oosting, RM Egeler, H Gelderblom, AHM Taminiou and PCW Hogendoorn
- 2065** **Author Index**
- 2075** **Keyword Index**

An Epidemiology section appears in the odd-numbered issues of BJC

Copyright © 2009 Cancer Research UK

Subscribing organisations are encouraged to copy and distribute this table of contents for internal, non-commercial purposes

This issue is now available at:
www.bjcancer.com